^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Excerpt:
...Nucleophosmin-1 (NPM1)-mutated disease documented in a local or the Sponsor's central testing facility....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormality

Excerpt:
...NPM1-mutated disease documented in a local or the Sponsor’s central testing facility. ...
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

Published date:
03/04/2021
Excerpt:
Kronos Bio, Inc. (Nasdaq: KRON) today announced, following receipt of minutes from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), that the company will proceed with its plan to assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint in a registrational Phase 3 trial to support potential accelerated approval of entospletinib in patients newly diagnosed with NPM1-mutated acute myeloid leukemia (AML).
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

5037 Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

Published date:
11/02/2023
Excerpt:
Differential analyses of data from flow cytometry (AML-HP-FC Cohort) and single cell imaging (AML-sc-MI Cohort) demonstrated: 1) sensitivity to ENTO and LANRA (³ 1uM) was higher in NPM1 and FLT3 mutated AML samples…